{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:41:08Z","timestamp":1790642468835,"version":"4.1.0"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.2215\/cjn.03960318","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T09:25:19Z","timestamp":1532597119000},"page":"1765-1776","source":"Crossref","is-referenced-by-count":103,"title":["Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.2215","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct01616927","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01377246","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02127437","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01670110","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03203642","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02656017","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02903511","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02697617","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02140814","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03523728","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03487913","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Fouad T.","family":"Chebib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,7,26]]},"reference":[{"key":"B1-20230601","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"B2-20230601","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B3-20230601","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ekir.2017.01.003","article-title":"Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease","volume":"2","author":"Perrone","year":"2017","journal-title":"Kidney Int Rep"},{"key":"B4-20230601","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B5-20230601","first-page":"241","article-title":"Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression","volume":"31","author":"Kline","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B6-20230601","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s10278-017-9978-1","article-title":"Performance of an artificial multi-observer deep neural network for fully automated segmentation of polycystic kidneys","volume":"30","author":"Kline","year":"2017","journal-title":"J Digit Imaging"},{"key":"B7-20230601","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.kint.2017.03.026","article-title":"Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease","volume":"92","author":"Kline","year":"2017","journal-title":"Kidney Int"},{"key":"B8-20230601","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B9-20230601","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le Gall","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B10-20230601","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","article-title":"Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease","volume":"102","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Hum Genet"},{"key":"B11-20230601","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/ki.2014.120","article-title":"Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease","volume":"86","author":"Spithoven","year":"2014","journal-title":"Kidney Int"},{"key":"B12-20230601","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"B13-20230601","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B14-20230601","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jamainternmed.2017.4377","article-title":"Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: A systematic review and meta-analysis","volume":"177","author":"Malhotra","year":"2017","journal-title":"JAMA Intern Med"},{"key":"B15-20230601","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","article-title":"Systolic blood pressure reduction and risk of cardiovascular disease and mortality: A systematic review and network meta-analysis","volume":"2","author":"Bundy","year":"2017","journal-title":"JAMA Cardiol"},{"key":"B16-20230601","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/01.ASN.0000018407.60002.B9","article-title":"Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study","volume":"13","author":"Schrier","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B17-20230601","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1681\/ASN.V5122037","article-title":"Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease","volume":"5","author":"Klahr","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"B18-20230601","doi-asserted-by":"crossref","first-page":"342","DOI":"10.7326\/0003-4819-142-5-200503010-00009","article-title":"The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the modification of diet in renal disease study","volume":"142","author":"Sarnak","year":"2005","journal-title":"Ann Intern Med"},{"key":"B19-20230601","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"key":"B20-20230601","first-page":"1857","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: The HALT-PKD clinical trial","volume":"32","author":"Irazabal","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B21-20230601","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJM199010183231602","article-title":"The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease","volume":"323","author":"Chapman","year":"1990","journal-title":"N Engl J Med"},{"key":"B22-20230601","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0025-6196(12)61724-8","article-title":"Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease","volume":"66","author":"Torres","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"B23-20230601","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/ajh\/hpu028","article-title":"Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: A meta-analysis","volume":"27","author":"Graudal","year":"2014","journal-title":"Am J Hypertens"},{"key":"B24-20230601","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/ajh\/hpt294","article-title":"Sodium intake and renal outcomes: A systematic review","volume":"27","author":"Smyth","year":"2014","journal-title":"Am J Hypertens"},{"key":"B25-20230601","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1001\/jama.2016.4447","article-title":"Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease","volume":"315","author":"Mills","year":"2016","journal-title":"JAMA"},{"key":"B26-20230601","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1681\/ASN.2011040430","article-title":"Sodium intake, ACE inhibition, and progression to ESRD","volume":"23","author":"Vegter","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B27-20230601","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ki.2012.74","article-title":"Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers","volume":"82","author":"Lambers Heerspink","year":"2012","journal-title":"Kidney Int"},{"key":"B28-20230601","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/path.1956","article-title":"ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats","volume":"209","author":"Hamming","year":"2006","journal-title":"J Pathol"},{"key":"B29-20230601","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2215\/CJN.03250410","article-title":"Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease","volume":"6","author":"Torres","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B30-20230601","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.10.018","article-title":"Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease","volume":"91","author":"Torres","year":"2017","journal-title":"Kidney Int"},{"key":"B31-20230601","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000445959","article-title":"Hydration and chronic kidney disease progression: A critical review of the evidence","volume":"43","author":"Clark","year":"2016","journal-title":"Am J Nephrol"},{"key":"B32-20230601","doi-asserted-by":"crossref","first-page":"F261","DOI":"10.1152\/ajprenal.00345.2014","article-title":"Effects of hydration in rats and mice with polycystic kidney disease","volume":"308","author":"Hopp","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"B33-20230601","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/ndt\/gfu093","article-title":"Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?","volume":"29","author":"Higashihara","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B34-20230601","doi-asserted-by":"crossref","first-page":"e018794","DOI":"10.1136\/bmjopen-2017-018794","article-title":"Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD)","volume":"8","author":"Wong","year":"2018","journal-title":"BMJ Open"},{"key":"B35-20230601","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1681\/ASN.2008111205","article-title":"Bicarbonate supplementation slows progression of CKD and improves nutritional status","volume":"20","author":"de Brito-Ashurst","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B36-20230601","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1681\/ASN.2011020175","article-title":"Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition","volume":"22","author":"Zoccali","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B37-20230601","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/ki.2010.375","article-title":"Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate","volume":"79","author":"Pavik","year":"2011","journal-title":"Kidney Int"},{"key":"B38-20230601","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1681\/ASN.2014020205","article-title":"Current status of bicarbonate in CKD","volume":"26","author":"Dobre","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B39-20230601","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2015020132","article-title":"Food restriction ameliorates the development of polycystic kidney disease","volume":"27","author":"Warner","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B40-20230601","doi-asserted-by":"crossref","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","article-title":"A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease","volume":"310","author":"Kipp","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"B41-20230601","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B42-20230601","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B43-20230601","doi-asserted-by":"crossref","first-page":"e0170017","DOI":"10.1371\/journal.pone.0170017","article-title":"Efficacy of statin treatment in early-stage chronic kidney disease","volume":"12","author":"Cho","year":"2017","journal-title":"PLoS One"},{"key":"B44-20230601","first-page":"563","article-title":"European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants","volume":"33","author":"Harris","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"B45-20230601","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000463063","article-title":"Polycystic kidney disease and the vasopressin pathway","volume":"70","author":"van Gastel","year":"2017","journal-title":"Ann Nutr Metab"},{"key":"B46-20230601","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2215\/CJN.08690813","article-title":"Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients","volume":"9","author":"Zittema","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B47-20230601","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","article-title":"Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function","volume":"65","author":"Boertien","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B48-20230601","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B49-20230601","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1124\/jpet.114.213256","article-title":"Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury","volume":"349","author":"Aihara","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"B50-20230601","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jcph.880","article-title":"Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: Phase 2 trials for dose selection in the pivotal phase 3 trial","volume":"57","author":"Shoaf","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"B51-20230601","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int"},{"key":"B52-20230601","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/ki.2013.285","article-title":"Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease","volume":"84","author":"Boertien","year":"2013","journal-title":"Kidney Int"},{"key":"B53-20230601","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"B54-20230601","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"B55-20230601","article-title":"Long-term effect of tolvaptan on renal function in autosomal dominant polycystic kidney disease","author":"Edwards","year":"in press","journal-title":"Clin J Am Soc Nephrol"},{"key":"B56-20230601","first-page":"34A","article-title":"Copeptin, a surrogate for Vasopressin, predicts disease progression and Tolvaptan treatment efficacy in ADPKD. Results of the TEMPO 3:4 trial","volume":"27","author":"Gansevoort","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B57-20230601","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032,5\u2032-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"B58-20230601","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/apt.13301","article-title":"Somatostatin analogues improve health-related quality of life in polycystic liver disease: A pooled analysis of two randomised, placebo-controlled trials","volume":"42","author":"Neijenhuis","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"B59-20230601","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): A randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"B60-20230601","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"B61-20230601","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"B62-20230601","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.02650313","article-title":"Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study","volume":"9","author":"Braun","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B63-20230601","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.09900915","article-title":"SIRENA 2 Study Group: Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4","volume":"11","author":"Ruggenenti","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B64-20230601","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1681\/ASN.2016111232","article-title":"Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease","volume":"28","author":"Tesar","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B65-20230601","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MNH.0000000000000333","article-title":"Therapeutic microRNAs in polycystic kidney disease","volume":"26","author":"Yheskel","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201811000-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:38:09Z","timestamp":1786369089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201811000-00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,26]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.03960318","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733703836.793555206","asserted-by":"object"}]},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,26]]}}}